290 likes | 454 Views
Highlights of the Day: <br />LYMPHOMA. Presented By Sonali Smith at 2014 ASCO Annual Meeting. Abstracts. Presented By Sonali Smith at 2014 ASCO Annual Meeting. Diffuse Large B-cell Lymphoma: How can we improve on R-CHOP?. Presented By Sonali Smith at 2014 ASCO Annual Meeting. Slide 4.
E N D
Highlights of the Day: <br />LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting
Abstracts Presented By Sonali Smith at 2014 ASCO Annual Meeting
Diffuse Large B-cell Lymphoma: How can we improve on R-CHOP? Presented By Sonali Smith at 2014 ASCO Annual Meeting
Slide 4 Presented By Sonali Smith at 2014 ASCO Annual Meeting
Rituximab clearance by age and gender and study design Presented By Sonali Smith at 2014 ASCO Annual Meeting
Slide 6 Presented By Sonali Smith at 2014 ASCO Annual Meeting
Slide 7 Presented By Sonali Smith at 2014 ASCO Annual Meeting
Diffuse Large B-cell Lymphoma: How can we improve on R-CHOP? Presented By Sonali Smith at 2014 ASCO Annual Meeting
Synthetic lethality of lenalidomide in ABC-DLBCL and clinical proof of principle Presented By Sonali Smith at 2014 ASCO Annual Meeting
PFS by GCB vs. non-GCB Subtype* in RCHOP Case-matched Control and R2CHOP Patients Presented By Sonali Smith at 2014 ASCO Annual Meeting
OS by GCB vs. non-GCB Subtype in RCHOP Case-matched Control and R2CHOP Patients Presented By Sonali Smith at 2014 ASCO Annual Meeting
PFS by Treatment Type in GCB vs. non-GCB Subtype Presented By Sonali Smith at 2014 ASCO Annual Meeting
Abstracts Presented By Sonali Smith at 2014 ASCO Annual Meeting
FL survival is improving for most patients Presented By Sonali Smith at 2014 ASCO Annual Meeting
Abstract 8502:<br />246 patients with reviewed postinduction PET-CT<br /> Presented By Sonali Smith at 2014 ASCO Annual Meeting
CT & BM based response (IWC 1999 criteria) Presented By Sonali Smith at 2014 ASCO Annual Meeting
Both PET cut-offs predictive of PFS Presented By Sonali Smith at 2014 ASCO Annual Meeting
Postinduction PET status (cut-off ≥4) <br />and Overall Survival Presented By Sonali Smith at 2014 ASCO Annual Meeting
Abstracts Presented By Sonali Smith at 2014 ASCO Annual Meeting
Mantle Cell Lymphoma 2014 Presented By Sonali Smith at 2014 ASCO Annual Meeting
CHOP ± Rituximab in MCL: <br />Progression-Free Survival Presented By Sonali Smith at 2014 ASCO Annual Meeting
Approved agents for R/R MCL<br />(Variable intensity of prior Rx among studies) Presented By Sonali Smith at 2014 ASCO Annual Meeting
LYM-3002: Replace vincristine with bortezomib Presented By Sonali Smith at 2014 ASCO Annual Meeting
Superior PFS by IRC with VR-CAP vs R-CHOP: 59% improvement Presented By Sonali Smith at 2014 ASCO Annual Meeting
Peripheral Neuropathy Presented By Sonali Smith at 2014 ASCO Annual Meeting
Conclusions – Efficacy Presented By Sonali Smith at 2014 ASCO Annual Meeting
Abstracts Presented By Sonali Smith at 2014 ASCO Annual Meeting
Take-home points Presented By Sonali Smith at 2014 ASCO Annual Meeting